Results 61 to 70 of about 2,864 (172)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis

Emerging Infectious Diseases, 2017
We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency.
Andrey Maryandyshev, Emanuele Pontali, Simon Tiberi, Onno Akkerman, Shashank Ganatra, Tsetan Dorji Sadutshang, Jan-Willem Alffenaar, Rohit Amale, Jai Mullerpattan, Sonam Topgyal, Zarir Farokh Udwadia, Rosella Centis, Lia D’Ambrosio, Giovanni Sotgiu, Giovanni Battista Migliori   +14 more
doaj   +1 more source

Functionalized Polydopamine Nanoparticles: A Promising Drug Delivery Platform for the Treatment of Tuberculosis

Drug Development Research, Volume 86, Issue 4, June 2025.
ABSTRACT Tuberculosis (TB) is considered a major infectious disease by the World Health Organization. The WHO estimates that there are 1.8 million TB deaths, and 10.4 million new cases of the disease reported yearly. While there are conventional therapies for TB, they have drawbacks such as a lengthy pill regimen, rigorous scheduling, and protracted ...
Nnamdi Ikemefuna Okafor, Precious Nnaji, Ngozi Francisca Nnolum‐Orji, Yahya E. Choonara   +3 more
wiley   +1 more source

Effect of delamanid on interim outcomes of bacteriological conversion amongst pediatric drug resistant tuberculosis cases in India

Lung India
Aim: To determine the bacteriological conversion rate after 6 months of Delamanid (DLM) based treatment in children with drug-resistant tuberculosis (DR-TB) and determine factors associated with bacteriological conversion.
Dhruv Kalawadia, Darshini Gandhi, Tsering Y Dirkhipa, Akanksha Jaiswal, Daksha Shah, Jyoti Salve, Malik Parmar, Kuldeep S Sachdeva, Minnie Bodhanwala, Ira Shah   +9 more
doaj   +1 more source

Novel Metronidazole Conjugates as Antimicrobial Agents

Drug Development Research, Volume 86, Issue 4, June 2025.
ABSTRACT Metronidazole (MTZ) is one of the oldest and still used anti‐infective nitroimidazole group drug. Although it is effective against anaerobic bacteria, protozoa, and parasites in clinical settings, it lacks efficacy against aerobic microorganisms.
Erol Akgün, Melike Demirayak, Leyla Yurttaş, Ülkiye Dudu Gül, Şeref Demirayak   +4 more
wiley   +1 more source

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations

Drug Design, Development and Therapy, 2016
Minhui Hu,1 Chunlan Zheng,1 Feng Gao2 1Department of Internal Medicine – Section 5, Wuhan Pulmonary Hospital (Wuhan Tuberculosis Control Institute), 2Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of ...
Hu MH, Zheng CL, Gao F
doaj  

Delamanid expanded access novel treatment of drug resistant tuberculosis

Infection and Drug Resistance, 2015
Roxana Rustomjee,1 Alimuddin Zumla2,31South African Medical Research Council, Cape Town, South Africa; 2Division of Infection and Immunity, University College London, London, UK; 3NIHR Biomedical Research Centre, University College Hospitals NHS ...
Rustomjee R, Zumla A
doaj  

Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China

International Journal of Infectious Diseases, 2019
Objective: Hong Kong is a high-income city of China with an intermediate tuberculosis (TB) burden, and 1% of TB cases are multidrug-resistant (MDR-TB).
Qianqian Fan, Wai-kit Ming, Wai-ying Yip, Joyce H.S. You   +3 more
doaj   +1 more source

Delamanid [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance Mycobacterium tuberculosis in Shanghai, China

Infection and Drug Resistance, 2023
Yinjuan Guo,1 Jinghui Yang,1 Weiping Wang,1 Xiaocui Wu,1 Baoshan Wan,1 Hongxiu Wang,1 Wei Sha,2 Fangyou Yu1 1Department of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China ...
Guo Y, Yang J, Wang W, Wu X, Wan B, Wang H, Sha W, Yu F   +7 more
doaj  

CRISPR Screening and Comparative LC‐MS Analysis Identify Genes Mediating Efficacy of Delamanid and Pretomanid against Mycobacterium tuberculosis

Advanced Science
Tuberculosis (TB), the leading cause of death from bacterial infections worldwide, results from infection with Mycobacterium tuberculosis (Mtb). The antitubercular agents delamanid (DLM) and pretomanid (PMD) are nitroimidazole prodrugs that require ...
Mei‐Yi Yan, Haifeng Li, Yun‐Mo Qu, Si‐Shang Li, Dandan Zheng, Xiao‐Peng Guo, Zhaojun Wu, Jie Lu, Yu Pang, Weimin Li, Jian Yang, Lingjun Zhan, Yi‐Cheng Sun   +12 more
doaj   +1 more source